Market Access · Pricing · Policy

Access strategy for
a repriced world.

The rules governing how drugs get assessed, priced, and accessed are being rewritten simultaneously — and evidence, policy and pricing can no longer be treated as separate decisions. We work directly with senior biotech and pharma leadership when the standard playbook no longer applies and the stakes are real.

Our services Point of View →
Evidence Pricing Policy LSA ACCESS STRATEGY

JCA has changed when EU access strategy must begin. MFN is linking US prices to European HTA outcomes. Cost-effectiveness thresholds are being reset by trade negotiations, not health economics. And CSRD double materiality requirements are making access and pricing decisions visible to investors and boards in ways they weren't before. Most teams are treating these as separate challenges. They're not — and that's where strategy breaks down. Our work starts at that intersection.

Services

Focused engagements.
Decision-ready outputs.

Short-burn, high-impact work designed for the moments when the standard playbook doesn't apply and the stakes are high. Scope, duration, and fees are tailored to the complexity of each situation — initial engagements typically start from 1–2 weeks.

01

Phase 2 Exit Readiness: EU Access Positioning

Rapid assessment of EU access viability, pricing corridor, HTA risks, and launch sequencing — designed for asset partnering and out-licensing readiness. Payer credibility drives asset valuation.

Outputs Pricing corridor · Access feasibility · HTA risk map · Key trade-offs and strategic options
Scoped to complexity From 1–2 weeks
02

Evidence → HTA Translation Sprint

Translate complex, early, or imperfect evidence into a credible payer narrative. Identify where your evidence package holds under EU HTA scrutiny — and where it doesn't. Build a mitigation strategy around what's missing.

Outputs Value story · HTA risk assessment · Evidence gap analysis · Mitigation strategy
Scoped to complexity From 1–2 weeks
03

Policy Risk & Pricing Scenario Map

Scenario modelling under EU HTA, IRP, and MFN pressure. Understand the pricing implications of the current policy environment and build a sequencing strategy that holds across scenarios.

Outputs Scenario map · Strategic pricing options · Launch sequencing framework · Risk-adjusted recommendations
Scoped to complexity From 1–2 weeks
04

Access & Pricing Diligence

For investors assessing EU market access risk on pipeline assets. High-conviction, fast-turnaround perspective on reimbursement viability, pricing ceiling, and HTA exposure — structured for deal timelines, not consulting cycles.

Outputs Access feasibility verdict · Pricing ceiling assessment · HTA risk profile · Key risks and mitigants
Scoped to complexity From 1 week
How we work

Access strategies fail where evidence, policy, and commercial expectations diverge and no one is holding the thread. That gap is the structural reality of access decisions today — and the work LSA exists to do.

About

Independent. Senior. In the room.

Faisal Latif

"Access strategies don't fail on design. They fail when evidence, policy, and commercial expectations diverge and no one is holding the thread. That's the work."

Latif Strategic Advisory is a senior-led, independent strategic advisory at the intersection of market access, pricing, evidence strategy, and policy. We work directly with senior biotech and pharma leadership — CEO, CCO, head of access — on the decisions where the stakes are real and the standard playbook doesn't apply.

Founded by Faisal Latif, who combines in-house operator experience with senior advisory practice. At Bristol Myers Squibb, Faisal led HEOR for the flagship thoracic oncology portfolio at the UK affiliate, delivering NICE reimbursement for BMS's breakthrough indication in first-line lung cancer, before moving into global access and pricing, ultimately heading the EU Cluster VAP organisation. At IQVIA, as Senior Principal in Value & Access within the EMEA Life Sciences Strategy practice, he directed advisory mandates helping global and ex-US pharma leadership navigate rapidly evolving regulatory and policy dynamics — EU JCA, IRA, and MFN — to build launch and pricing strategy across Europe and Asia.

LSA works at the point where access strategy becomes a live commercial challenge — when evidence is still evolving, policy is shifting, and the distance between what's planned and what's achievable is starting to show. Increasingly, that work extends to the sustainability dimension: CSRD double materiality requirements mean that access decisions — how medicines are priced, distributed, and made available — are becoming investor and disclosure questions, not just payer ones.

Founder

Latif Strategic Advisory

Senior Principal · Value & Access, EMEA Life Sciences Strategy

IQVIA

Head, EU Cluster · Value, Access & Pricing

Bristol Myers Squibb

HEOR Lead, Thoracic Oncology · UK Affiliate

Bristol Myers Squibb

MSc, Health Economics & International Health Policy

London School of Economics and Political Science

Focus areas

EU HTA (JCA) · Pricing strategy · MFN/IRP · Early access planning · Oncology

Strategic Expert Advisory Panel

Senior expertise, configured per engagement.

A curated panel of senior independent specialists — engaged selectively to bring depth where it matters: comparative-evidence framing, national HTA insight, global access policy, and equitable access in emerging markets. The profiles below are representative — not exhaustive. Specific configurations are agreed per mandate.

01

Anchor — Health Economics & Pharmaceutical Policy

Senior European academic and pharmaceutical pricing authority. Advisory experience across EU institutions, national HTA bodies, and the WHO. Brings comparative-evidence framing and academic-policy credibility to mandates where the question is contested.

02

Global Health Policy & Equitable Access

Senior biopharma access strategist working at the intersection of corporate access strategy, global health policy, and equitable access in lower- and middle-income markets. Brings the lens regulators, investors, and patient stakeholders increasingly insist on — and the credibility to land it.

03

Former Senior Payer — Germany

G-BA / AMNOG-orbit expertise. First-hand insight into how access narratives land with German payers, including for advanced therapies and specialty assets.

04

Former Senior Payer — France

HAS / CEPS-orbit expertise. Senior view on French HTA dynamics, comparative-effectiveness framing, and the texture of national pricing negotiation.

Strategic Network

A curated network. Not a one-firm answer.

Where mandates demand depth LSA does not hold internally, we operate through curated strategic partnerships — assembled per engagement. The result is specialist depth without the bureaucracy of a global firm, and breadth a single boutique cannot match.

01

Sustainability & CSRD Reporting

Engaged through a specialist sustainability and ESG reporting partner. For double materiality operationalisation, access-and-equity disclosure under CSRD, and investor-facing sustainability narratives in pharma.

02

Transactional, BD&L & M&A Advisory

Engaged through a US-based transactional advisor specialising in pharma BD&L, M&A, and deal flow. For PE, VC, and hedge-fund-facing engagements — access and pricing diligence shaped to investor decision cycles.

03

US Payer & Health Policy Dynamics

Engaged through a US payer-strategy partner network for mandates touching ICER, the IRA, MFN, and US–EU pricing-cascade strategy.

Point of View

Point of View.

Whether you're six months from a Phase 2 readout without an EU pricing view, navigating a negative HTA signal, or building a launch sequencing strategy under MFN and IRP pressure — these are the forces shaping what's possible. EU HTA reform (JCA), Most Favored Nation pricing, and the politicisation of cost-effectiveness thresholds are repricing European pharma in parallel. These pieces examine what that means for access and pricing strategy — and where the decisions are still yours to shape.

MFN · JCA · Evidence · New

The Compounding Is Real. Here’s What the Data Shows.

A peer-reviewed analysis puts empirical numbers on the MFN × JCA pressure for the first time. Launch rates in JCA states fell 37.8%. The orphan differential hit 22%. The findings are sharper than anticipated — and the window to act is narrowing.

23 June 2026 · Full article · 4 min read MFN · Europe · Pricing · Co-authored with JMUN ADVISORS

Go Ahead — De-Prioritise Europe. You Can't De-Prioritise the Exposure.

The frustration with Europe is rational. The instinct to retreat is understandable. But de-prioritising Europe doesn't resolve the MFN exposure — it just removes the revenue while leaving the risk intact. The feedback loop, the three structural paths, and what the investor lens is actually asking.

11 June 2026 · Full article · 5 min read CSRD · ESG · Market Access

CSRD Is Not a Sustainability Problem. It's an Access-Strategy Problem.

CSRD double materiality puts pricing and patient access on the regulatory disclosure agenda — simultaneously as an impact risk and a financial risk. Most pharma organisations are not prepared for the question the regulation is actually asking.

3 June 2026 · Full article China · Diligence · Market Access

The Access Blind Spot in China-Licensed Assets

The China asset wave is being priced as an innovation story. Diligence is valuing the science and the deal — but not whether the asset can be reimbursed in the West. The three access gaps that go unpriced — and why the fix is earlier diligence, not more of it.

21 May 2026 · Full article EU HTA · Ex-US Access · Precedent

The First JCA Has Landed. Here's What It Actually Tells Us.

The EU's first Joint Clinical Assessment — Ipsen's Ojemda — is complete. Four reads from the precedent: speed is real, it bites first where evidence is thinnest, scale is arriving fast, and the framing no longer belongs to you.

26 May 2026 · Full article HTA · Pricing · MFN · Long Read

The EU Access Playbook Is Breaking. Here's Exactly Where.

JCA, MFN and shifting reference baskets have collapsed what were sequential decisions into one that must be made earlier than the data support. A 35% decline in EU launches. 578 days to patient access. Where strategy breaks down — and the human cost of getting it wrong.

19 May 2026 · Full article HTA · Policy

The US spent 30 years calling European drug prices too low. MFN benchmarks against them.

The contradiction at the heart of Most Favored Nation pricing — and what it means for the credibility of HTA as a neutral process.

12 May 2026 Pricing · MFN

NICE thresholds are no longer purely a health economics tool. They are instruments of trade policy.

The first threshold change since NICE was founded in 1999 — announced alongside a trade deal. The technical clothing remains. The emperor underneath has changed.

9 May 2026 MFN · Market Access

Senior leadership is hedging on MFN. Market access teams can't.

With GLOBE taking effect October 1, the decisions being made in the vacuum of leadership silence are still decisions. They're just being made by default instead of by design.

7 May 2026
Selected Work

Engagements that shaped decisions.

A selection of advisory engagements. Client details are anonymised.

Oncology · Companion Diagnostics · Market Access

Companion Diagnostic Access Strategy

A major global oncology alliance was preparing to launch a novel ADC asset in platinum-resistant ovarian cancer requiring a companion diagnostic to identify eligible patients. Across 17 European and select international markets, CDx reimbursement pathways were fragmented, inconsistent, and in many cases untested for novel IHC-based diagnostics. Reliable funding could not be assumed to follow regulatory approval.

A structured three-phase engagement mapped CDx funding pathways and key stakeholders across all markets, segmented them by gap severity and mitigation feasibility, and produced a strategic playbook covering 7+ actionable options — from manufacturer funding models to policy shaping — each assessed by timing, effort, and risk. Validated throughout with in-country P&MA experts across EU4 and select global markets.

The alliance entered launch sequencing with a defensible, evidence-based playbook. CDx reimbursement gaps were identified and categorised before regulatory approval — enabling proactive rather than reactive management. The above-asset framework was designed for reuse across future pipeline assets.

17 Markets covered
8–9 wks Delivery sprint
>€100K Engagement value
Won Competitive mandate
View case study
Immunology · EU HTA · Pricing Strategy

EU HTA Advisory & Early Access Strategy

A US-headquartered specialty biopharma was preparing simultaneous HTA submissions in three major EU markets for a novel oral treatment in a moderate-to-severe immunological condition — the first in its mechanism class to reach late-stage development. With NICE, G-BA, and HAS submissions running in parallel, the team needed rapid, independent advisory support to stress-test the HEOR framing and sharpen the payer narrative before dossiers were locked.

A focused two-week sprint reviewed the evidence package against current HTA methodology in each market, identified where the value story was vulnerable, and produced a concise HTA risk map with market-specific recommendations. The engagement led to a follow-on mandate: early access strategy for a late-stage pipeline asset, covering scenario modelling under EU HTA and IRP, launch sequencing across five EU markets, and a pricing corridor framework.

Dossiers submitted with strengthened HEOR rationale across all three markets, on schedule. The pricing corridor was established six months ahead of the first EU HTA assessment. The pipeline asset sequencing framework was adopted as the basis for the global launch plan.

3 HTA markets
2 wks Initial sprint
6 months Pre-assessment delivery
Won Follow-on mandate
View case study
Contact

Start a conversation.

Whether you're leading an asset, running a transaction, or building your team's access capability — if the situation is complex and the stakes are real, let's talk. Engagements begin with a short scoping call. No proposals, no procurement process.

Reach Faisal directly

faisal@latifstrategic.co.uk
LinkedIn latifstrategic.com Point of View